Bibliography
- Holby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med 2011;9:32-8
- Gaspar MC, Couet W, Olivier J-C, et al. Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review. Eur J Clin Microbiol Infect Dis 2013;32:1231-52
- Kim W, Tengra FK, Young Z, et al. Spaceflight promotes biofilm formation by Pseudomonas aeruginosa. PLoS One 2013;8:e62437
- Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2004;2:95-108
- Merlo CA, Boyle MP, Diener-West M, et al. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest 2007;132:562-8
- Ren CL, Konstan MW, Yegin A, et al. Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis. J Cyst Fibros 2012;11:293-9
- Hauser AR. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat Rev Microbiol 2009;7:654-65
- Epelman S, Bruno TF, Neely GG, et al. Pseudomonas aeruginosa exoenzyme S induces transcriptional expression of proinflammatory cytokines and chemokines. Infect Immun 2000;68:4811-14
- Wareham DW, Curtis MA. A genotypic and phenotypic comparison of type III secretion profiles of Pseudomonas aeruginosa cystic fibrosis and bacteremia isolates. Int J Med Microbiol 2007;297:227-34
- Frank DW, Vallis A, Wiener-Kronish JP, et al. Generation and characterisation of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis 2002;186:64-73
- Lynch SV, Flanagan JL, Sawa T, et al. Polymorphisms in the Pseudomonas aeruginosa type III secretion protein, PcrV - Implications for anti–PcrV immunotherapy. Microb Pathog 2010;48:197-204
- Francois B, Luyt C-E, Dugard A, et al. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonised with Pseudomonas aeruginosa: a randomised, double-blind, placebo-controlled trial. Crit Care Med 2012;40:2320-6
- Milla CE, Chmiel JF, Accurso FJ, et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatr Pulmonol 2013, doi:10.10002/ppul:22890
- U.S. FDA grants orphan drug designation for KaloBios' KB001-A in treatment of cystic fibrosis patients, Kalabios Pharmaceuticals, Inc. Available from: http://ir.kalobios.com/releasedetail.cfm?ReleaseID=801591
- U.S. Food and Drug administration, Orphan drug designation and approvals. Available from: http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=398013